CLINICAL BENEFIT WITH REGORAFENIB ACROSS SUBGROUPS AND POST-PROGRESSION IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST) AFTER PROGRESSION ON IMATINIB (IM) AND SUNITINIB (SU): PHASE 3 GRID TRIAL UPDATE
ANNALS OF ONCOLOGY(2012)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络